Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management

Pharmacological Research

Volumn 120, Issue , 2017, Pages 219-225

  Johnston, T P ^a   Korolenko, T A ^b   Pirro, M ^c   Sahebkar, A ^d  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b SCIENTIFIC RESEARCH INSTITUTE OF PHYSIOLOGY AND BASIC MEDICINE   (Russian Federation)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Hypercholesterolemia; Nutraceuticals

Indexed keywords

ANACETRAPIB; ANTILIPEMIC AGENT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EVACETRAPIB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NUTRACEUTICAL; POLYSACCHARIDE; TORCETRAPIB; BIOLOGICAL PRODUCT; HYPOCHOLESTEROLEMIC AGENT; ZYMOSAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DRUG EFFICACY; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MORBIDITY; REVIEW; RISK FACTOR; ANALYSIS; ANIMAL; COMPLICATION; DIETARY SUPPLEMENT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; HUMANS; HYPERCHOLESTEROLEMIA; RISK FACTORS; ZYMOSAN;

EID: 85017428214     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.04.008     Document Type: Review

References (98)

1. [1] Heart disease and stroke statistics – update. 2016, American Heart Association http://circ.ahajournals.org/content/133/4/447. (Accessed 9 August 2016).
2. [2] McGill, H.C., McMahon, A., Herderick, E.E., Malcom, G.T., Tracy, R.E., Strong, J.P., For the pathobiological determinants of atherosclerosis in youth (PDAY) research group: origin of atherosclerosis in childhood and adolescence. Am. J. Clin. Nutr. 72 (2000), 1307S–1315S.
3. [3] Napoli, C., Glass, C.K., Witztum, J.L., Deutsch, R., D'Armiento, F.P., Palinski, W., Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood: fate of Early Lesions in Children (FELIC) study. Lancet 354 (1999), 1234–1241.
4. [4] Pathological Determinants of Atherosclerotic in Youth (PDAY) Research Group, Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler. Thromb. 13 (1993), 1291–1298.
5. [5] Tracy, R.E., Newman, W.P. III, Wattigney, W.A., Histological features of atherosclerosis and hypertension from autopsies of young individuals in a defined geographic population: Bogalusa Heart Study. Atherosclerosis 116 (1995), 163–179.
6. [6] Berenson, G.S., Srinivasan, S., Cholesterol as a risk factor for early atherosclerosis: the Bogalusa Heart Study. Prog. Pediatr. Cardiol. 17 (2003), 113–122.
7. [7] Sattar, N., Preiss, D., Murray, H.M., Welsh, P., Buckley, B.M., de Craen, A.J., Seshasai, S.R., McMurray, J.J., Freeman, D.J., Jukema, J.W., Macfarlane, P.W., Packard, C.J., Stott, D.J., Westendorp, R.G., Shepherd, J., Davis, B.R., Pressel, S.L., Marchioli, R., Marfisi, R.M., Maggioni, A.P., Tavazzi, L., Tognoni, G., Kjekshus, J., Pedersen, T.R., Cook, T.J., Gotto, A.M., Clearfield, M.B., Downs, J.R., Nakamura, H., Ohashi, Y., Mizuno, K., Ray, K.K., Ford, I., Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375:9716 (2010), 735–742.
8. [8] Hu, M., Cheung, B.M.Y., Tomlinson, B., Safety of statins: an update. Ther. Adv. Drug Saf. 3:3 (2012), 133–144.
9. [9] Malik, P., Berisha, S.Z., Santore, J., Agatisa-Boyle, C., Brubaker, G., Smith, J.D., Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport. J. Lipid Res. 52:5 (2011), 951–957, 10.1194/jlr.M011122.
10. [10] Korolenko, T.A., Tuzikov, F.V., Cherkanova, M.S., Johnston, T.P., Tuzikova, N.A., Loginova, V.M., Filjushina, E.E., Kaledin, V.I., Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407. Can. J. Physiol. Pharmacol. 90:2 (2012), 141–153, 10.1139/y11-118.
11. [11] Korolenko, T.A., Kisarova, Y.A., Filjushina, E.E., Dergunova, M.A., Machova, E., Macrophage stimulation and β-D-glucans as biological response modifiers: the role in experimental tumor development. Takahashi, R., Kai, H., (eds.) Handbook of Macrophages: Life Cycle, Functions and Diseases, 2012, Nova Science Publishing, New York, 249–276.
12. [12] Brown, L., Rosner, B., Willett, W.W., Sacks, F.M., Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am. J. Clin. Nutr. 69:1 (1999), 30–42.
13. [13] Whitehead, A., Beck, E.J., Tosh, S., Wolever, T.M., Cholesterol-lowering effects of oat beta-glucan: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 100:6 (2014), 1413–1421.
14. [14] Napolitano, M., Sennato, S., Botham, K.M., Bordi, F., Bravo, E., Role of macrophage activation in the lipid metabolism of postprandial triacylglycerol-rich lipoproteins. Exp. Biol. Med. (Maywood), 238, 2013, 98.
15. [15] Greaves, D.R., Gordon, S., Thematic review series: the immune system and atherogenesis: recent insights into the biology of macrophage scavenger receptors. J. Lipid Res. 46:1 (2005), 11–20.
16. [16] Matthijsen, R.A., de Winther, M.P., Kuipers, D., van der Made, I., Weber, C., Herias, M.V., Gijbels, M.J., Buurman, W.A., Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density-lipoprotein receptor-deficient mice. Circulation 119 (2009), 2188–2195.
17. [17] Nguyen, D.G., Hildreth, J.E., Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 33:2 (2003), 483–493.
18. [18] Korolenko, T.A., Rukavishnikova, E.V., Safina, A.F., Dushkin, M.I., Mynkina, G.I., Endocytosis by liver cells during suppression of intralysosomal proteolysis. Biol. Chem. Hoppe Seyler 373:7 (1992), 573–580 (PMID: 1515086).
19. [19] Svechnikova, I.G., Korolenko, T.A., Stashko, JuF, Kaledin, V.I., Nikolin, V.P., Nowicky, J.W., The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy. Drugs Exp. Clin. Res. 24:5–6 (1998), 261–269.
20. [20] Korolenko, T.A., Johnston, T.P., Lykov, A.P., Shintyapina, A.B., Khrapova, M.V., Goncharova, N.V., Korolenko, E., Bgatova, N.P., Machova, E., Nescakova, Z., Sakhno, L.V., A comparative study of the hypolipidaemic effects of a new polysaccharide, mannan Candida albicans serotype A, and atorvastatin in mice with poloxamer 407-induced hyperlipidaemia. J. Pharm. Pharmacol. 68:12 (2016), 1516–1526.
21. [21] Alipour, A., Elte, J.W.F., van Zaanen, H.C.T., AP Rietveld, A.P. Rietveld, Castro-Cabezas, M., Novel aspects of postprandial lipemia in relation to atherosclerosis. Atheroscler. Suppl. 9 (2008), 39–44.
22. [22] Doi, K., Masuura, M., Kawara, A., Baba, S., Treatment of diabetes with glucomannan. Lancet 1 (1979), 987–988 (abstract).
23. [23] Arvill, A., Bodin, L., Effect of short-term ingestion of glucomannan on serum cholesterol in healthy men. Am. J. Clin. Nutr. 61 (1995), 585–589.
24. [24] Vuksan, V., Sievenpiper, J.L., Owen, R., Swilley, J.A., Spadafora, P., Jenkins, D.J., Vidgen, E., Brighenti, F., Josse, R.G., Leiter, L.A., Xu, Z., Novokmet, R., Beneficial effects of viscous dietary fiber from konjac-mannan in subjects with the insulin resistance syndrome. Diabetes Care 23 (2000), 9–14.
25. [25] Chen, H.L., Shen, W.H., Tai, T.S., Liaw, Y.P., Chen, Y.C., Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects − a randomized double-blinded trial. J. Am. Coll. Nutr. 22 (2003), 36–42.
26. [26] Doi, K., Nakamura, T., Aoyama, N., Matsuura, M., Kawara, A., Metabolic and nutritional effects of long-term use of glucomannan in the treatment of obese diabetics. Oomura, S., Tarui, S., (eds.) Progress in Obesity Research 1990. Proceedings of the Sixth International Congress on Obesity, 1990, John Libbey, London, 507–514.
27. [27] Huang, C.Y., Zhang, M.Y., Peng, S.S., Hong, J.R., Wang, X., Jiang, H.J., Zhang, F.L., Bai, Y.X., Liang, J.Z., Yu, Y.R., et al. Effect of konjac food on blood glucose level in patients with diabetes. Biomed. Environ. Sci. 3 (1990), 123–131.
28. [28] Doi, K., Effects of konjac fiber (glucomannan) on glucose and lipids. Eur. J. Clin. Nutr. 49 (1995), S190–S197.
29. [29] Vuksan, V., Sievenpiper, J.L., Xu, Z., Wong, E.Y., Jenkins, A.L., Beljan-Zdravkovic, U., Leiter, L.A., Josse, R.G., Stavro, M.P., Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J. Am. Coll. Nutr. 20 (2001), 370S–380S.
30. [30] Jones, P.J., Leitch, C.A., Pederson, R.A., Meal-frequency effects on plasma hormone concentrations and cholesterol synthesis in human. Am. J. Clin. Nutr. 57 (1993), 868–874.
31. [31] Lakshmanan, M.R., Nepokroeff, C.M., Ness, G.C., Dugan, R.E., Porter, J.W., Stimulation of insulin of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol synthesis activity. Biochem. Biophys. Res. Commun. 50 (1973), 704–710.
32. [32] Matsuura, M., Effects of dietary fiber (glucomannan) on serum cholesterol. Jpn. Soc. Clin. Nutr. 8 (1986), 1–11.
33. [33] Gallaher, C.M., Munion, J., Hesslink, R. Jr., Wise, J., Gallaher, D.D., Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J. Nutr. 130:11 (2000), 2753–2759.
34. [34] Livieri, C., Novanzi, F., Lorini, R., The use of highly-purified glucomannan-based fibers in childhood obesity. Pediatr. Med. Chir. 14 (1992), 196–198.
35. [35] Sood, N., Baker, W.L., Coleman, C.I., Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am. J. Clin. Nutr. 88:4 (2008), 1167–1175.
36. [36] Pollack, O.J., Reduction of blood cholesterol in man. Circulation 2 (1953), 702–706.
37. [37] Klingberg, S., Andersson, H., Mulligan, A., Bhaniani, A., Welch, A., Bingham, S., Khaw, K.T., Andersson, S., Ellegard, L., Food sources of plant sterols in the EPIC Norfolk population. Eur. J. Clin. Nutr. 62:6 (2008), 695–703.
38. [38] Valsta, L.M., Lemstrom, A., Ovaskainen, M.L., Lampi, A.M., Toivo, J., Korhonen, T., Piironen, V., Estimation of plant sterol and cholesterol intake in Finland: quality of new values and their effect on intake. Br. J. Nutr. 92:4 (2004), 671–678.
39. [39] Weststrate, J.A., Meijer, G.W., Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolemic and mildly hypercholesterolemic subjects. Eur. J. Clin. Nutr. 52 (1998), 334–343.
40. [40] Hallikainen, M.A., Sarkkinen, E.S., Gylling, H., Erkkila, A.T., Uusitupa, M.I.J., Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low fat diet. Eur. J. Clin. Nutr. 54 (2000), 715–725.
41. [41] Vanstone, C.A., Raeini-Sarjaz, M., Parsons, W.E., Jones, P.J., Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am. J. Clin. Nutr. 76 (2002), 1272–1278.
42. [42] Varady, K.A., Ebine, N., Vanstone, C.A., Parsons, W.E., Jones, P.J., Plant sterols and endurance training combine to favorably alter plasma lipid profiles in previously sedentary hypercholesterolemic adults after 8 wk. Am. J. Clin. Nutr. 80 (2004), 1159–1166.
43. [43] Ikeda, I., Tanaka, K., Sugano, M., Vahouny, G.V., Gallo, L.L., Inhibition of cholesterol absorption in rats by plant sterols. J. Lipid Res. 29 (1988), 1573–1582.
44. [44] Nissinen, M., Gylling, H., Vuoristo, M., Miettinen, T.A., Micellar distribution of cholesterol and phytosterols after duodenal plant sterol ester infusion. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002), G1009–G1015.
45. [45] Yoshida, M., Vanstone, C.A., Parsons, W.D., Zawistowski, J., Jones, P.J.H., Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur. J. Clin. Nutr. 60:4 (2006), 529–537.
46. [46] Gylling, H., Plat, J., Turley, S., Ginsberg, H.N., Ellegard, L., Jessup, W., Jones, P.J., Lutjohann, D., Maerz, W., Masana, L., Silbernagel, G., Staels, B., Boren, J., Catapano, A.L., De Backer, G., Deanfield, J., Descamps, O.S., Kovanen, P.T., Riccardi, G., Tokgozoglu, L., Chapman, M.J., European atherosclerosis society consensus panel on phytosterols. Atherosclerosis 232:2 (2014), 346–350.
47. [47] Dong, H., Wang, N., Zhao, L., Lu, F., Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Evid. Based Complement. Altern. Med, 2012, 2012, 591654, 10.1155/2012/591654.
48. [48] Dong, H., Zhao, Y., Zhao, L., Lu, F., The effects of berberine on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Planta. Med. 79:6 (2013), 437–446.
49. [49] Lan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., Sun, G., Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipidemia, and hypertension. J. Ethnopharmacol. 161 (2015), 69–81.
50. [50] Doggrell, S.A., Berberine a novel approach to cholesterol lowering. Expert Opin. Invest. Drugs 14:5 (2005), 683–685.
51. [51] Cicero, A.F.G., Rosticci, M., Parini, A., Morbini, M., Urso, R., Grandi, E., Borghi, C., Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level, and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutrition J., 14(30), 2015, 10.1186/s12937-015-0019-y.
52. [52] Mannarino, M.R., Ministrini, S., Pirro, M., Nutraceuticals for the treatment of hypercholesterolemia. Eur. J. Intern. Med. 25:7 (2014), 592–599.
53. [53] Liu, J., Zhang, J., Shi, Y., Grimsgaard, S., Alraek, T., Fonnebo, V., Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin. Med., 23(November (1)), 2006, 4.
54. [54] Gerards, M.C., Terlou, R.J., Yu, H., Koks, C.H., Gerdes, V.E., Traditional Chinese lipid-lowering agent red yeast rise results in significant LDL reduction but safety is uncertain − a systematic review and meta-analysis. Atherosclerosis 240:2 (2015), 415–423.
55. [55] Pirro, M., Lupattelli, G., Del Giorno, R., Schillaci, G., Berisha, S., Mannarino, M.R., Bagaglia, F., Melis, F., Mannarino, E., Nutraceutical combination (red yeast rise, berberine, and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients. PharmaNutrition 1:2 (2013), 73–77.
56. [56] Pirro, M., Mannarino, M.R., Bianconi, V., Simental-Mendia, L.E., Bagaglia, F., Mannarino, E., Sahebkar, A., The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 110:August (2016), 76–88, 10.1016/j.phrs.2016.04.021.
57. [57] Pirro, M., Mannarino, M.R., Ministrini, S., Fallarino, F., Lupattelli, G., Bianconi, V., Bagaglia, F., Mannarino, E., Effects of a nutraceutical combination on lipids, inflammation, and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci. Rep., 23(6), 2016, 23587, 10.1038/srep23587.
58. [58] Cai, H., Harrison, D.G., Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87 (2000), 840–844.
59. [59] Cicero, A.F.G., Morbini, M., Rosticci, M., D'Addato, S., Grandi, E., Borghi, C., Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity, and arterial stiffness in moderately hypercholesterolemic subjects. Ann. Nutr. Metab. 68 (2016), 213–219.
60. [60] Cicero, A.F., Colletti, A., Rosticci, M., Grandi, E., Borghi, C., Efficacy and tolerability of a combined lipid-lowering nutraceutical on cholesterolemia, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. J. Biol. Regulators Homeostat. Agents 30:2 (2016), 593–598.
61. [61] Sahebkar, A., Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol., 11(2), 2014, 123, 10.1038/nrcardio.2013.140-c1.
62. [62] Panahi, Y., Khalili, N., Hosseini, M.S., Abbasinazari, M., Sahebkar, A., Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement. Ther. Med. 22:5 (2014), 851–857.
63. [63] Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L.E., Sahebkar, A., Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J. Cardiovasc. Pharmacol. 68:3 (2016), 223–229.
64. [64] Sampson, U.K., Fazio, S., linton, MF Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep. 14:1 (2012), 1–10.
65. [65] Sahebkar, A., Saboni, N., Pirro, M., Banach, M., Curcumin: an effective adjunct in patients with statin-associated muscle symptoms. J. Cachexia Sarcopenia Muscle, 2016, 10.1002/jcsm.12140.
66. [66] Sahebkar, A., Henrotin, Y., Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials. Pain Med. 17:6 (2016), 1192–1202.
67. [67] Sahebkar, A., Cicero, A.F.G., Simental-Mendia, L.E., Aggarwal, B.B., Gupta, S.C., Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 107 (2016), 234–242.
68. [68] Karimian, M.S., Pirro, M., Majeed, M., Sahebkar, A., Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 33 (2017), 55–63.
69. [69] Ghandadi, M., Sahebkar, A., Curcumin: an effective inhibitor of interleukin-6. Curr. Pharm. Des., 2016, 10.2174/1381612822666161006151605.
70. [70] Karimian, M.S., Pirro, M., Johnston, T.P., Majeed, M., Sahebkar, A., Curcumin and endothelial function: evidence and mechanisms of protective effects. Curr. Pharm. Des., 2017, 10.2174/1381612823666170222122822.
71. [71] Stein, E.A., Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol. Metab. Clin. North Am. 38 (2009), 99–119.
72. [72] Toth, P.P., Antisense therapy and emerging applications for the management of dyslipidemia. J. Clin. Lipidol. 5 (2011), 441–449.
73. [73] Kastelein, J.J., Wedel, M.K., Baker, B.F., Su, J., Bradley, J.D., Yu, R.Z., Chuang, E., Graham, M.J., Crooke, R.M., Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein. Circulation 114 (2006), 1729–1735.
74. [74] Geary, R.S., Baker, B.F., Crooke, S.T., Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein. B. Clin. Pharmacokinet. 54:2 (2015), 133–146.
75. [75] Cuchel, M., Bloedon, L., Szapary, P., Kolansky, D.M., Wolfe, M.L., Sarkis, A., Millar, J.S., Ikewaki, K., Siegelman, E.S., Gregg, R.E., Rader, D.J., Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356 (2007), 148–156.
76. [76] Patel, R.S., Scopelliti, E.M., Savelloni, J., Therapeutic management of familial hypercholesterolemia: current and emerging drug therapies. Pharmacotherapy 35:12 (2015), 1189–1203.
77. [77] Juxtapid (lomitapide) Package Insert. 2015, Aegerion Pharmaceuticals, Inc., Cambridge, MA.
78. [78] Yadav, K., Sharma, M., Ferdinand, K.C., Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors: present perspectives and future horizons. Nutr. Metabol. Cardiovasc. Dis. 26:10 (2016), 853–862.
79. [79] Mullard, A., Cholesterol-lowering blockbuster candidates speed into Phase III trials. Nat. Rev. Drug Discov. 11 (2012), 817–819.
80. [80] Farnier, M., PCSK9 inhibitors. Curr. Opin. Lipidol. 24 (2013), 251–258.
81. [81] McDonagh, M., Peterson, K., Holzhammer, B., Fazio, S., A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J. Manag. Care Spec. Pharm. 22:6 (2016), 641–653.
82. [82] Praluent (alirocumab) Package Insert. 2015, Sanofi-Aventis U.S. LLC, Bridgewater, NJ.
83. [83] Repatha (evolocumab) Package Insert. 2015, Amgen, Inc, Thousand Oaks, CA.
84. [84] McKenney, J.M., Koren, M.J., Kereiakes, D.J., Hanotin, C., Ferrand, A., Stein, E.A., Safety and efficacy of a monoclonal antibody to proprotein convertase subtilizing/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59 (2012), 2344–2353.
85. [85] Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., Liebow, A., Bettencourt, B.R., Sutherland, J.E., Hutabarat, R.M., Clausen, V.A., Karsten, V., Cehelsky, J., Nochur, S.V., Kotelianski, V., Horton, J., Mant, T., Chiesa, J., Ritter, J., Munisamy, M., Vaishnaw, A.K., Gollob, J.A., Simon, A., Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomized, single-blind, placebo-controlled, phase 1 trial. Lancet 383:January (9911) (2014), 60–68, 10.1016/s0140-6736(13)61914-5.
86. [86] Gilham, D., Wasiak, S., Tsujikawa, L.M., Halliday, C., Norek, K., Patel, R.G., Kulikowski, E., Johansson, J., Sweeney, M., Wong, N.C., RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises apoA-I/HDL, and represses pathways that contribute to cardiovascular disease. Atherosclerosis 247:April (2016), 48–57, 10.1016/j.atherosclerosis.2016.01.036.
87. [87] Yamashita, S., Matsuzawa, Y., Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Curr. Opin. Lipidol. 27:5 (2016), 459–472.
88. [88] Ikewaki, K., Rader, D.J., Sakamoto, T., Nishiwaki, M., Wakimoto, N., Schaefer, J.R., Ishikawa, T., Fairwell, T., Zech, L.A., Nakamura, H., Nagano, M., Brewer, H.B. Jr., Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92 (1993), 1650–1658.
89. [89] Barter, P.J., Caulfield, M., Eriksson, M., Grundy, S.M., Kastelein, J.J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.C., Waters, D.D., Shear, C.L., Revkin, J.H., Buhr, K.A., Fisher, M.R., Tall, A.R., Brewer, B., Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357 (2007), 2109–2122.
90. [90] Sirtori, C.R., Mombelli, G., Viability of developing CETP inhibitors. Cardiovasc. Ther. 26 (2008), 135–146.
91. [91] Miller, N.E., CETP inhibitors and cardiovascular disease: time to think again. F1000Res, 3, 2014, 124.
92. [92] Hovingh, G.K., Ray, K.K., Boekholdt, S.M., Is cholesteryl ester transfer protein inhibition an effective strategy to reduce cardiovascular risk? CETP as a target to lower CVD risk: suspension of disbelief?. Circulation 132 (2015), 433–440.
93. [93] Schaefer, E.J., Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Curr. Opin. Lipidol. 24 (2013), 259–264.
94. [94] AbuMweis, S.S., Jew, S., Ames, N.P., Beta-glucan from barley and its lipid-lowering capacity: a meta-analysis of randomized, controlled trials. Eur. J. Clin. Nutr. 64:12 (2010), 1472–1480.
95. [95] Chua, M., Baldwin, T.C., Hocking, T.J., Chan, K., Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E. Br. J. Ethnopharmacol. 128:2 (2010), 268–278.
96. [96] Wu, T., Fu, J., Yang, Y., Zhang, L., Han, J., The effects of phytosterols/stanols on blood lipid profiles: a systematic review with meta-analysis. Asia Pac. J. Clin. Nutr. 18:2 (2009), 179–186.
97. [97] Li, Y., Jiang, L., Jia, Z., Xin, W., Yang, S., Yang, Q., Wang, L., A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One, 9(6), 2014, e98611, 10.1371/journal.pone.0098611.
98. [98] Sahebkar, A., A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin. Nutr. 33:3 (2014), 406–414.